[company_age]7.0[/company_age][employees]11-50 employees[/employees][funding]Mise de fonds initiale[/funding][description]Dianosic is a French medical technology company specializing in the development of innovative intranasal drug delivery solutions for chronic respiratory and central nervous system diseases. The company's mission is to improve patient quality of life by providing minimally invasive, non-surgical treatment options that address unmet clinical needs. Dianosic's flagship product is the Active Resorbable Intranasal Scaffold (ARIS) platform, which delivers targeted, sustained-release medication to the nasal cavity. This innovative technology has the potential to revolutionize the management of chronic diseases such as rhinitis, rhinosinusitis, and central nervous system disorders. Dianosic's unique approach to drug delivery addresses the challenges of patient adherence and treatment efficacy, offering a promising alternative to traditional medication regimens. The company's strong team of experienced professionals, including physicians, scientists, and engineers, is dedicated to developing and commercializing innovative solutions that improve patient outcomes and transform the healthcare landscape.[/description][ps]Active Resorbable Intranasal Scaffolds (ARIS) platform for chronic respiratory and central nervous system diseases.[/ps]